Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
about
The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapyAntigen-specific immunotherapy of cervical and ovarian cancerCRPV genomes with synonymous codon optimizations in the CRPV E7 gene show phenotypic differences in growth and altered immunity upon E7 vaccinationImmunotherapy for cervical cancer: Research status and clinical potentialLow-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responsesA conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers.Recombinant lipidated HPV E7 induces a Th-1-biased immune response and protective immunity against cervical cancer in a mouse model.Vaccines: past, present and future.Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses.Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial.A comparison of clinically utilized human papillomavirus detection methods in head and neck cancer.Therapeutic Vaccine Strategies against Human Papillomavirus.Natural killer cells: role in local tumor growth and metastasisProgress in the development of a cervical cancer vaccine.Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: a meta-analysis.Immunotherapy for gynaecological malignancies.Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.Gene therapy in gynecological cancer.Preventive and Therapeutic Vaccines against Human Papillomaviruses Associated Cervical CancersHuman papillomavirus vaccines for the treatment of cervical cancer.Human papillomavirus therapeutic vaccines in head and neck tumors.HPV Vaccines: today and in the Future.Prevention and Inhibition of TC-1 Cell Growth in Tumor Bearing Mice by HPV16 E7 Protein in Fusion with Shiga Toxin B-Subunit from shigella dysenteriae.Protective immunity with an E1 multivalent epitope DNA vaccine against cottontail rabbit papillomavirus (CRPV) infection in an HLA-A2.1 transgenic rabbit modelTherapeutic vaccination of rabbits with a ubiquitin-fused papillomavirus E1, E2, E6 and E7 DNA vaccine.Therapeutic vaccines against human papillomavirus and cervical cancer.Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studiesCervical Cancer: Development of Targeted Therapies Beyond Molecular Pathogenesis.Human papillomavirus as a target for management, prevention and therapy.Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer.Cell-mediated immune response: a clinical review of the therapeutic potential of human papillomavirus vaccination.The contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL /6 mouse model.Proceedings From the First Asia-Oceania Research Organisation on Genital Infections and Neoplasia (AOGIN) MeetingTargeted immunotherapy of high-grade cervical intra-epithelial neoplasia: Expectations from clinical trials.Translational fusion and redirection to thylakoid lumen as strategies to enhance accumulation of human papillomavirus E7 antigen in tobacco chloroplasts.Murine HPV16 E7-expressing transgenic skin effectively emulates the cellular and molecular features of human high-grade squamous intraepithelial lesions.Therapeutic human papillomavirus vaccines: current clinical trials and future directionsEmerging human papillomavirus vaccines
P2860
Q26744087-BC1ACAA9-DAFA-431E-9CB7-570AA703B7E7Q27488697-91C33AC8-0865-4791-9522-4F51398CDF64Q28473368-14244040-4928-4D1A-BF00-EA6D1CB0B121Q34033763-14BDDC7E-63B6-40B0-8F52-1FBEA0BEF609Q34045548-1D646233-81CD-46FA-8E6A-5B92FF5C77BFQ34121681-F5A49D55-058C-42E1-9EA2-1ED21F79D606Q34345467-C812CDBC-2286-4B2D-808B-8E4623AE1A36Q34409178-6FCE5CE2-B43A-4F2C-BBC1-72857AC7A7B1Q35049821-06F15C84-3374-4602-B0F8-63BCEFBFF925Q35055665-B7EE0AD4-7023-4E07-8A17-A073026D690BQ35169110-A6E196DF-B249-4319-ADC8-6DCB969AC263Q35826752-16D0B41C-74C5-47E6-8E35-C9FF7FB95991Q35905953-EF94CFD4-D121-49D4-A3A4-FBDFCE64AAA1Q35919119-B066E09E-58C8-4BEA-B4E3-DD8A0AC18BD8Q36237280-EA9A6B97-A76F-4B72-8ECA-DE40C9CCE5DDQ36239661-D9232E09-C7CE-497E-965B-DA3F7EAEDB62Q36373370-36E0F661-BDBE-475E-AD41-A39BDC528176Q36532089-38813689-CC34-45C1-BAC2-6FA11C21549AQ36652548-019EEF40-215E-42B8-BEC9-87565D2ED44BQ36690278-29E21888-43CD-42F4-9702-8D4F1286C2E7Q36817148-EF6D22AD-7C4A-4419-99AD-0C80560314EAQ36976268-C38FC8C0-4046-488A-BCB6-04D3F1EC2E28Q37017281-1588EF9A-8FC2-4912-8B95-5BE210E00B74Q37208345-5C0F313E-1E8D-435C-9DFD-E98F493380BCQ37240133-6A49A89B-B49F-4531-8C45-39362E49842EQ37418916-50D745DB-9FA9-4A0F-8955-3793D95E4845Q37494787-7FEBFC2E-90EE-47D5-B716-7633BE6EAB6BQ37579334-D9AD50F0-7637-4EF3-8980-694EBD56B40CQ38018120-96F04D14-DA33-4CA8-9481-2E8FFBA6AFB8Q38089937-BD1BFFCD-D0EA-42AA-8694-33C2373A8D64Q38242083-2CB134A5-1291-410F-A6CD-CD2C11BB5A4CQ39474019-2806D0AC-EC85-4F34-9E93-4698A088A8C4Q45812304-A91D3949-23DD-43CA-B1CE-D57DD6E0E10CQ50052586-734983F5-3C1A-4D57-B984-77358F7470D3Q51070857-9DA85BA4-5E42-4DD8-975F-C0E1DA0FCC63Q54937688-4D6695F8-01B0-4964-A931-2887E223498DQ56937332-ECF83D16-C52F-41BD-8D4A-420BCC96E4B5Q56967486-D74BE218-AA3B-4796-89B2-21721DAE22D6
P2860
Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Phase I/II trial of immunogeni ...... cal intraepithelial neoplasia.
@en
Phase I/II trial of immunogenicity of a human papillomavirus
@nl
type
label
Phase I/II trial of immunogeni ...... cal intraepithelial neoplasia.
@en
Phase I/II trial of immunogenicity of a human papillomavirus
@nl
prefLabel
Phase I/II trial of immunogeni ...... cal intraepithelial neoplasia.
@en
Phase I/II trial of immunogenicity of a human papillomavirus
@nl
P2093
P1476
Phase I/II trial of immunogeni ...... cal intraepithelial neoplasia.
@en
P2093
Anne-Cécile Lagrost
Aude Beliard
Colette Gerday
Frédéric Buxant
Frédéric Maudoux
Isabelle Fayt
Jacques Boniver
Jean Doyen
Jean-Christophe Noël
Nathalie Jacobs
P2888
P304
P356
10.1007/S00262-004-0501-4
P577
2004-02-17T00:00:00Z
P5875
P6179
1050260080